{"analyses":[{"ciLowerLimit":"0.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.59","estimateComment":"Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Log Rank Test stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).","paramType":"Hazard Ratio (HR)","paramValue":"0.33","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Kaplan-Meier Estimate of median DOR and 95% CI were not reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Kaplan-Meier estimate of upper 95% CI for median DOR was not reached.","groupId":"OG001","lowerLimit":"11.9","upperLimit":"NA","value":"13.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"description":"Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Acalabrutinib 100 mg orally twice a day","id":"OG000","title":"Arm A: Acalabrutinib Monotherapy"},{"description":"Idelalisib+Rituximab or Bendamustine + Retuximab","id":"OG001","title":"Arm B: Investigator's Choice"}],"paramType":"MEDIAN","populationDescription":"Intent to treat (ITT) population including all randomized participants","reportingStatus":"POSTED","timeFrame":"IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up","title":"Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.","type":"SECONDARY","unitOfMeasure":"Months"}